Jiangsu Nhwa Pharmaceutical Co., Ltd.
恩华药业
002262
Shenzhen Stock Exchange
Company Profile
1. Company’s development strategy focuses on the market of central nerve system (CNS) drugs, and NHWA is the nationally designated manufacturing base for narcotic and psychotropic drugs withintegrated product line, which constitutes its unique core competitiveness. 2. The projects under developmentcover main kinds of CNS drugs. The R&D centre is in the domestic leading position in chemical synthesis and the development of new dosage forms including sustained release preparations, injectable emulsions, orally disintegrating tablets and dispersible tablets etc. Multiple inventionpatents have been submitted and authorized. 3. Board of directors pays high attention to the research and development and supportsa lot in funds and talents. Nhwa has possessed a quite powerful team of researchers and expertswith ability on the development of brandnew drugs. Nhwa has established an integratedplatform for the study of innovative psychotropic drugs and analgesic drugs. 4. Nhwais highly recognized in pharmaceutical industry with the establishment of characteristic sale network in specialized CNS market after continuously and frequently holding academic activities about anesthesiology, psychiatry and neurology. 5. Nhwa possesses all the manufacturing processes including the synthesis of API and the production of finished products. The extension of production and business makes profit marginhigher.
Full description
Jiangsu Nhwa Pharmaceutical Co.,?Ltd?was initially founded in 1978. In year 2008, Nhwa was listed on the Shenzhen stock exchange with the stock code 002262. Nhwa Pharma integrates R&D, manufacturing and marketing together, becoming a nationally designated manufacturingbase forpsychotropic drugs, a national high-tech enterprise, one of top 100Chinese pharmaceutical companies, a national intellectual property rights demonstration company,one of 20 national star companies within 20 years in medical quality management, an international environmental certification (ISO14000) confirmed?enterprise, the first batch of innovative enterprises in Jiangsu province,?and?vice President unit of China?Narcotic Drug Association.?"Nhwa" trademark is a national famous trademark. The company is mainly engaged in the production and sales of CNS drugs and is strategically oriented inthe field of CNS.?Nhwa Pharma typically is a company in China that fully focuses on the market segments?of CNS drug products, including anesthesiology, psychiatry and neurology. Through years of unremitting efforts in product development, production and service, the company has established a complete series of CNS?drug products and marketing network?and played an important role in the manufacture and?sales of CNS drugs in China. In addition, there are series of cardiovascular products in different R&D stages. Nhwa’s new anti-hypertension?drug, namedasIptakalim, is developed cooperatively with Academy of Military Medical Sciences. Iptakalim, as a domestic and international initiative, has a brand-new chemical structure and mechanism of action. It takes a leading position in the world and gradually occupies?cardiovascular drugs market with broad?prospects. Nhwa pharma has three large scale pharmaceutical GMP production bases of APIs?and finishedproducts?with?an area of over 900?Chinese mu. The company owns national certificated?workshops?of APIs, solid preparations, liquid injections,lyophilized powder with more than 10 production lines?fortablets, capsules, small volume?injections and powder for injections.?At present, Nhwa has the yearly production capacity of 300 tons for over 30kinds of APIs,3 billion tablets and capsules,?100 millioninjectable unitsfor over 40 kinds of finished products.? According to the development strategy,?the company continuously makes?efforts in?energy conservation and environment protection, having passed the international environment authentication?(ISO14000). We will strive to develop the export business of APIs and finished products, and prepare for the EMA and FDA approval to get a place in the international market. ? The company places a great value on technological innovation, development of new products and the cooperation with universitiesor institutes. Nhwa R&D centerhas national reputation.It is ranked as a provincial engineering technology center, enterprise academician workstation and national postdoctoral research station, conducting many national key research projects.